Literature DB >> 1082488

Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes.

A N Theofilopoulos, L H Perrin.   

Abstract

Immunofluorescence studies showed that properdin (P) and factor B bind to C3-C3b receptor bearing human lymphoblastoid cells (Raji, Daudi) and B type human peripheral lymphocytes (HPL). P bound to Raji cells first incubated with normal human serum (NHS). EDTA, but not EGTA, halted the binding of P to cells incubated with NHS. However, fixation of P to Raji cells, after incubation with NHS first reacted with inulin, was independent of Ca++ and -g++ ions. Fixation of P to Raji cells depended on the presence of C3 or C3b and occurred in the absence of factor D and factor B. Binding of P to B type HPL was detectable only after incubation of these cells with NHS first reacted with inulin; under these conditions binding of P to Raji cells was also greatly enhanced. With both Raji cells and HPL, factor B was detectable on cell surfaces only after incubation of these cells with NHS first reacted with activators of the P system. Binding of factor B to cells required the presence of C3b and binding or stabilization of cell bound factor B necessitated the presence of activated P. P and factor B were detectable only on cultured cells having C3-C3b receptors. However, incubation of NHS with all lymphoblastoid cell lines studied resulted in activation of P and cleavage of factor B. Binding of P and factor B to cells may follow one of three sequences; (a) activated P in fluid phase combines with C3, factor D, and factor B, and the whole complex fixes to cellular C3-C3b receptors via its C3 moiety; (b) C3b generated in fluid phase combines with P, C3, factor D, and factor B and binds to C3-C3b receptors; or (c) C3 or C3b first binds onto the C3-C3b receptors and thereafter interacts with P, factor D, And factor B. Binding of components of the P system to cells or other particles may relate to such biological phenomena as lysis, phagocytosis, proliferation, attraction of other cell types, and alteration of responsiveness to external stimuli.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1082488      PMCID: PMC2190117          DOI: 10.1084/jem.143.2.271

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  The effect of anticomplementary substances on properdin in normal and C2-deficient sera.

Authors:  R H McLean; K Townsend; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

2.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

3.  Hybridization of Burkitt lymphoblastoid cells.

Authors:  R Glaser; F J O'Neill
Journal:  Science       Date:  1972-06-16       Impact factor: 47.728

4.  Reaction mechanism of the alternative pathway of complement fixation.

Authors:  P J Lachmann; P Nicol
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

5.  The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.

Authors:  V Brade; A Nicholson; G D Lee; M M Mayer
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

6.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

7.  Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.

Authors:  A N Theofilopoulos; F J Dixon; V A Bokisch
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

8.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

9.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.

Authors:  A N Theofilopoulos; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

View more
  13 in total

1.  Detection of circulating immune complexes with a modified Raji cell technique.

Authors:  T H Hütteroth; K H Meyer zum Büschenfelde
Journal:  Klin Wochenschr       Date:  1977-09-15

2.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Activation of the alternative pathway of complement by Entamoeba histolytica.

Authors:  L Ortiz-Ortiz; R Capin; N R Capin; B Sepúlveda; G Zamacona
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

4.  Solubilization of an activity regulating C3b function from Raji cell membranes.

Authors:  P Carlson; S Ruddy; D H Conrad
Journal:  Immunology       Date:  1982-05       Impact factor: 7.397

5.  Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.

Authors:  J G Sissons; M B Oldstone; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

6.  Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.

Authors:  R C Gupta; F C McDuffie; G Tappeiner; R E Jordon
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

7.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

Authors:  O F Ramos; G Sármay; E Klein; E Yefenof; J Gergely
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 8.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 9.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

10.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.

Authors:  N R Cooper; F C Jensen; R M Welsh; M B Oldstone
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.